TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $4.67 Consensus Price Target from Analysts

TScan Therapeutics, Inc. (NASDAQ:TCRX) has been given a consensus recommendation of “Hold” by the eight research firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $2.6667.

A number of equities analysts have weighed in on the stock. HC Wainwright downgraded shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price for the company. in a research note on Tuesday. Benchmark reissued a “buy” rating on shares of TScan Therapeutics in a research note on Thursday, August 13th. Weiss Ratings lowered shares of TScan Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Lifesci Capital cut shares of TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, June 23rd.

Institutional Trading of TScan Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TCRX. Boothbay Fund Management LLC boosted its stake in shares of TScan Therapeutics by 50.0% in the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock valued at $35,000 after purchasing an additional 8,121 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of TScan Therapeutics by 6.0% during the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock worth $235,000 after buying an additional 9,676 shares during the last quarter. Bank of America Corp DE raised its stake in shares of TScan Therapeutics by 48.7% during the first quarter. Bank of America Corp DE now owns 57,529 shares of the company’s stock worth $58,000 after buying an additional 18,829 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in TScan Therapeutics by 8.5% in the second quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company’s stock valued at $417,000 after buying an additional 22,642 shares during the period. Finally, Panagora Asset Management Inc. acquired a new position in TScan Therapeutics in the fourth quarter valued at approximately $25,000. 82.83% of the stock is owned by institutional investors.

TScan Therapeutics Trading Down 4.3%

Shares of TScan Therapeutics stock opened at $0.33 on Monday. TScan Therapeutics has a 12-month low of $0.33 and a 12-month high of $2.57. The stock has a market capitalization of $22.37 million, a P/E ratio of -0.36 and a beta of 1.07. The company has a 50-day simple moving average of $0.79 and a 200 day simple moving average of $0.97. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.31.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. TScan Therapeutics had a negative return on equity of 108.72% and a negative net margin of 1,655.35%.The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.88 million. Research analysts expect that TScan Therapeutics will post -1.11 earnings per share for the current fiscal year.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.